Lung Cancer Surgery in Brazil Trends and Forecast
The future of the lung cancer surgery market in Brazil looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets. The global lung cancer surgery market is expected to reach an estimated $5.7 billion by 2031 with a CAGR of 3.4% from 2025 to 2031. The lung cancer surgery market in Brazil is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.
• Lucintel forecasts that, within the product type category, surgical device is expected to witness the highest growth over the forecast period.
• Within the end use category, ambulatory surgical center is expected to witness the highest growth over the forecast period.
Emerging Trends in the Lung Cancer Surgery Market in Brazil
Brazil’s lung cancer surgery market is experiencing a transformative phase, propelled by a push toward modern surgical techniques, expanding regional capacity, and integrating technology. As the nation grapples with high smoking prevalence and urban pollution, demand for minimally invasive procedures is mounting. Urban hubs such as São Paulo and Rio de Janeiro are leading the adoption of VATS and robotic-assisted thoracic surgery, while government investment under public health initiatives is widening access. With growing training programs and equipment production, Brazil is positioning itself as a regional leader in thoracic oncology innovation and care delivery.
• Rapid Expansion of VATS Nationwide: Video-assisted thoracoscopic surgery (VATS) has surged in popularity, increasing from under half of lung resections in 2015 to around 80% by 2020 among academic centers. The widespread uptake reflects benefits including smaller incisions, reduced pain, and shorter hospital stays. Hospitals in major cities are now consistently performing complex resections via VATS, and national training programs are helping disseminate best practices to regional hospitals, supporting broader adoption.
• Growing Adoption of Robotic-Assisted Thoracic Surgery (RATS): Robotic-assisted surgery is becoming more prevalent, with about 10% of lung resections now using robotic platforms. With over 80 robotic systems installed nationwide, Brazil is rapidly expanding its use, with dedicated programs in cities beyond the largest centers. Outcomes show low complication and conversion rates, and emerging national certification initiatives are supporting safe, standardized adoption for complex cancer cases.
• Increase in Sublobar and Segmental Resections: Surgeons are increasingly conducting lung-sparing procedures—segmentectomy and sublobar resections—especially for small, early-stage tumors using minimally invasive techniques. This trend conserves lung function and offers similar cancer outcomes to full lobectomy while benefiting older and lower-risk patients. The increase is driven by improved diagnostic imaging and data from Brazilian centers supporting the safety and efficacy of these targeted resections.
• National SBCT Database Enables Quality Tracking: A national thoracic surgery registry has been tracking over 9,000 procedures since 2015, enabling benchmarking, identifying trends, and monitoring regional disparities. This data collection supports research, quality improvement, and policy decisions by allowing clinicians to track VATS vs open surgery adoption and patient outcomes. This evidence base is fostering broader use of minimally invasive approaches and standardizing surgical performance across Brazil.
• Training and Regional Dissemination of Techniques: Brazilian thoracic surgery programs are establishing formal training modules in VATS and RATS, including hands-on fellowships at top centers. Workshops sponsored by surgical societies are improving technical skills nationwide. This investment in education is enabling more surgeons, even in second-tier cities, to implement minimally invasive procedures, addressing access gaps and reducing concentration of advanced surgery in only a few urban areas.
Brazil’s lung cancer surgery field is shifting decisively toward minimally invasive, data-driven, and better-equipped practice. With widespread adoption of VATS, growing robotic use, expanded segmental resections, robust national data collection, and enhanced training infrastructure, the market is transforming patient care. These trends signal a more modern, equitable model of thoracic oncology across Brazil, improving access and outcomes while building capacity for future innovation.
Recent Developments in the Lung Cancer Surgery Market in Brazil
Brazil is enhancing its lung cancer care infrastructure through catalytic actions—wider surgical access, adoption of modern techniques, policy support, and improved recovery pathways. Public health programs and private systems are working in unison to dismantle geographic and systemic barriers, enabling comprehensive treatment networks and better outcomes across the country.
• Government‑Backed “Mais Especialidades” Program: This federal initiative is upgrading regional hospitals with thoracic surgery capabilities by funding VATS equipment and training. The aim is to decentralize cancer care and reduce patient travel burdens. Initial beneficiaries include state capitals and major secondary cities, broadening access to early-stage surgery and enabling standardized cancer protocols outside major urban centers.
• Partnerships with Multinational Device Companies: Brazilian hospitals are collaborating with Medtronic, J&J, and local manufacturers to pilot advanced surgical platforms. These partnerships enable access to the latest-generation VATS and robotic systems, supported by ongoing clinical training and maintenance. Such alliances accelerate technological adoption and signal a growing role in global thoracic device supply chains.
• Expansion of Post‑Operative Tele‑Rehabilitation Programs: To enhance recovery and reduce hospital readmissions, tele-rehabilitation programs are being rolled out, offering patients at-home physical therapy, counseling, and monitoring. These services are integrated with national registry data to personalize recovery plans, resulting in faster recovery and better long-term lung function.
• Publication of Brazilian BRAVO Trial Results: The BRAVO randomized trial comparing robotic and VATS lobectomy has been completed, offering robust outcome data. Preliminary analysis suggests that robotic lobectomy is at least as safe and effective as VATS, with similar oncologic results. Publication of these findings supports evidence-based decision-making and may influence reimbursement and adoption of robotic techniques nationally.
• Expansion of Public Lung Cancer Screening Pilots: Several states have launched low-dose CT screening programs integrated with surgical teams to streamline care pathways. Early data indicate increased detection of stage I tumors and faster referral to surgical units. These tactics align with global screening guidelines and are enabling timely, curative-stage resections.
Recent developments in Brazil’s lung cancer surgery landscape—government-sponsored access programs, device partnerships, tele-rehab, clinical trial data, and CT screening pilots—underscore a sophisticated, patient-focused, and system-wide modernization effort. These advances are enhancing surgical access, improving outcomes, and cementing Brazil’s position as a pioneering force in Latin American thoracic oncology.
Strategic Growth Opportunities for Lung Cancer Surgery Market in Brazil
Brazil leads Latin America in lung cancer surgery innovation, driven by rising incidence, expanded public-private healthcare access, and growing adoption of minimally invasive and robotic techniques. Investments under decentralization programs and increased diagnostic capacity are reshaping surgical pathways. These developments open fertile ground for growth across outpatient resection, robotics, imaging integration, telehealth, and advanced perioperative solutions. As both public and private sectors modernize, these opportunities are enhancing treatment access, outcomes, and system efficiency in Brazil’s lung cancer surgery landscape.
• Expansion of Minimally Invasive VATS Programmes in Regional Hospitals: Video-assisted thoracic surgery is being deployed across major cities and expanding to regional centers, offering smaller incisions, faster recovery, and reduced complication rates. As early-stage detection increases through low-dose CT screening pilots, hospitals are deploying high-quality imaging and reusable thoracoscopic instrument sets. Device manufacturers that offer cost-effective VATS platforms and sustainable service models stand to gain from Brazil’s effort to decentralize lung cancer surgical services.
• Growth in Robotic-Assisted Thoracic Surgery at Major Cancer Centres: Top hospitals have implemented robotic thoracic systems, demonstrating high rates of complete resection, low mortality, and short hospital stays. Robotic-assisted lobectomy and segmentectomy programmes are expanding within leading centres, showing promising safety and effectiveness. Suppliers offering robotic units, instruments, training, and cost-sharing models can leverage the growing demand in both private and academic oncology centres.
• Ambulatory and Day Surgery Lobectomy Models: With the national health system and private insurers under cost pressure, early-stage procedures via VATS or robotics are shifting to outpatient settings. Modular surgical units and enhanced anesthetic protocols make same-day discharge possible. Vendors that provide compact equipment packages, workflow training, and telemonitoring support align with hospital ambitions to expand ambulatory thoracic surgery and lower inpatient use.
• Integration of AI-Based Imaging and Preoperative Planning Tools: AI-powered imaging platforms are emerging to assist in lesion detection, segmentation, and surgical planning. Brazilian research centres are participating in validation studies, enhancing local acceptance. Integration with CT and PET systems supports precision surgery via virtual planning of resection margins and lymph node mapping. Providers offering AI solutions validated in Brazil and aligned with hospital imaging infrastructure can support growth across surgical pathways.
• Adoption of Telehealth-Enabled Postoperative Care: Telehealth is increasingly used to support remote monitoring of postoperative lung cancer patients, especially outside urban centres. Virtual check-ins, symptom tracking, and coordination with community health providers improve outcomes and reduce readmissions. Developers offering secure platforms compliant with Brazilian health standards and integrated with hospital EHR systems can capture new opportunities in remote surgical recovery support.
Brazil’s lung cancer surgery market is rapidly evolving with expanded VATS and robotic programmes, ambulatory surgery models, AI planning integration, and telehealth-supported care. These applications enhance access, outcomes, and efficiency across diverse regions. As system modernisation and public-private investments continue, Brazil is poised to become the region’s leader in advanced thoracic surgical care.
Lung Cancer Surgery Market in Brazil Driver and Challenges
Brazil’s lung cancer surgery market reflects strategic health investments, expanding diagnostic infrastructure, and adoption of advanced platforms. Key drivers include rising cancer incidence linked to tobacco use and pollution, national screening efforts, tech adoption, and surgical modernisation. However, regulatory complexity, high device costs, specialist shortages, and regional inequality create barriers. Understanding these dynamics is essential for targeting interventions that expand equitable surgical access and sustain growth.
The factors responsible for driving the lung cancer surgery market in Brazil include:
• Increasing Lung Cancer Detection from CT Screening Initiatives: Brazil’s medical associations are expanding low-dose CT screening guidelines to identify early-stage lung cancers. Earlier detection increases surgical referrals and drives adoption of VATS and robotics. As more cases are identified earlier, hospitals require investments in resection capacity. Stable procedural volume from screening justifies expansion in surgical tools and training.
• Government Investments in Regional Surgical Capacity: Initiatives are upgrading cancer care infrastructure in secondary cities. Subsidised procurement of VATS and robotic systems and training funding support decentralisation. Providers that collaborate with the government on rollout and financial models can maximise uptake of surgical technologies beyond metropolitan centres.
• Public-Private Expansion in Thoracic Oncology: Leading private hospitals are partnering with medical device companies to pilot advanced surgical programmes. These centres set clinical benchmarks and support broader surgeon training. Collaboration on outcome evidence, skills transfer, and device localisation can amplify system-wide adoption and support long-term scale.
• Advances in Surgical Technology and Integration: Technological progress in VATS, robotics, AI imaging, and telehealth is increasing performance and lowering morbidity. Local research participation enhances clinical confidence. Suppliers with integrated full-cycle solutions for planning, execution, and recovery can tap into hospitals seeking value-based and outcome-focused investments.
• Rising Lung Cancer Burden: Continued tobacco use, urban pollution, and ageing population are increasing lung cancer rates. The corresponding surgical workload requires expanded capacity. As demand grows, surgical solutions that improve efficiency and recovery will be prioritised by providers and payers.
Challenges in the lung cancer surgery market in Brazil are:
• High Cost and Import Dependency: Advanced surgical systems frequently depend on imports and attract import taxes, raising entry costs. High capital and consumable costs limit access, especially in public hospitals. Without flexible financing and local manufacturing strategies, adoption remains slow in many regions.
• Shortage of Thoracic Surgery Workforce: There is limited availability of trained thoracic surgeons and robotic surgical teams, especially in non urban centres. Training programmes and tele mentoring are expanding but capacity remains constrained. Without addressing workforce development, personnel remain a bottleneck for surgical capacity expansion.
• Regulatory Delays and Infrastructure Gaps: Regulatory review timelines can delay device introduction, and limited surgical infrastructure still exists in peripheral regions. Coordinated efforts across regulators, suppliers, and hospitals are needed to streamline device approvals and support theatre upgrades, enabling broader tech adoption.
Brazil’s lung cancer surgery market is advancing on the back of screening expansion, infrastructure investments, and tech innovation. Yet cost, workforce, and regulatory challenges persist. Overcoming these through collaborative financing, decentralised training, and streamlined device approvals will be key to achieving equitable, high quality surgical care nationally.
List of Lung Cancer Surgery Market in Brazil Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, lung cancer surgery companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lung cancer surgery companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Lung Cancer Surgery Market in Brazil by Segment
The study includes a forecast for the lung cancer surgery market in Brazil by product type, surgery, and end use.
Lung Cancer Surgery Market in Brazil by Product Type [Analysis by Value from 2019 to 2031]:
• Surgical Devices
• Endosurgical Equipment
• Monitoring or Visualizing Equipment
Lung Cancer Surgery Market in Brazil by Surgery [Analysis by Value from 2019 to 2031]:
• Robotic Surgery
• Thoracotomy
• Video Assisted Surgery
• Percutaneous Surgery
• Endobronchial Surgery
Lung Cancer Surgery Market in Brazil by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Specialty Cancer Care Centers
• Ambulatory Surgical Centers
• Others
Features of the Lung Cancer Surgery Market in Brazil
Market Size Estimates: Lung cancer surgery in Brazil market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Lung cancer surgery in Brazil market size by product type, surgery, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different product type, surgery, and end use for the lung cancer surgery in Brazil.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lung cancer surgery in Brazil.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the lung cancer surgery market in Brazil?
Answer: The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.
Q2. What are the major segments for lung cancer surgery market in Brazil?
Answer: The future of the lung cancer surgery market in Brazil looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets.
Q3. Which lung cancer surgery market segment in Brazil will be the largest in future?
Answer: Lucintel forecasts that surgical device is expected to witness the highest growth over the forecast period.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the lung cancer surgery market in Brazil by product type (surgical devices, endosurgical equipment, and monitoring or visualizing equipment), surgery (robotic surgery, thoracotomy, video assisted surgery, percutaneous surgery, and endobronchial surgery), and end use (hospitals, specialty cancer care centers, ambulatory surgical centers, and others)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Lung Cancer Surgery Market in Brazil, Lung Cancer Surgery Market in Brazil Size, Lung Cancer Surgery Market in Brazil Growth, Lung Cancer Surgery Market in Brazil Analysis, Lung Cancer Surgery Market in Brazil Report, Lung Cancer Surgery Market in Brazil Share, Lung Cancer Surgery Market in Brazil Trends, Lung Cancer Surgery Market in Brazil Forecast, Lung Cancer Surgery Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.